Table 4. Comparison of clinical characteristics between the good responders and the poor responders in overall patients.
| Characteristic | Good responder (n=171) | Poor responder (n=239) | P value |
|---|---|---|---|
| Age, yr | 58.6±12.1 | 60.4±11.6 | 0.125 |
| Female, sex | 97 (56.7) | 139 (58.2) | 0.839 |
| Body mass index, kg/m2 | 27.6±4.9 | 27.0±4.5 | 0.264 |
| Duration of diabetes, yr | 11.1±8.2 | 12.5±8.2 | 0.091 |
| Subtype of SGLT2 inhibitor, dapagliflozin:empagliflozin | 137:34 | 190:49 | 0.901 |
| Hypertension | 121 (70.8) | 176 (73.6) | 0.575 |
| Dyslipidemia | 145 (84.8) | 203 (84.9) | 0.968 |
| HbA1c, % | 8.8±1.3 | 8.3±1.0 | <0.001 |
| Fasting plasma glucose, mg/dL | 162.7±42.3 | 152.3±42.4 | 0.015 |
| Fasting C-peptide, ng/mL | 2.6±1.6 | 2.5±1.4 | 0.609 |
| Fasting insulin, mIU/L | 17.2±10.0 | 12.7±5.0 | 0.216 |
| HOMA-β | 58.8±49.0 | 62.1±27.4 | 0.682 |
| HOMA-IR | 7.1±3.6 | 4.6±2.0 | 0.044 |
| eGFR, mL/min/1.73 m2 | 93.1±23.9 | 89.7±4.5 | 0.137 |
| Insulin therapy | 54 (31.6) | 100 (41.8) | 0.039 |
Values are presented as mean±standard deviation or number (%).
SGLT2, sodium-glucose cotransporter-2; HbA1c, glycosylated hemoglobin; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate.